Targeting gallbladder cancer: Oncolytic virotherapy with myxoma virus is enhanced by rapamycin in vitro and further improved by hyaluronan in vivo

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Weng, Mingzhe ^a   Gong, Wei ^a   Ma, Mingzhe ^a   Chu, Bingfeng ^a   Qin, Yiyu ^a   Zhang, Mingdi ^a   Lun, Xueqing ^b   McFadden, Grant ^c   Forsyth, Peter ^d   Yang, Yong ^a   Quan, Zhiwei ^a  

^a XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF FLORIDA   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Collagen IV; Gallbladder cancer; Myxoma virus; Oncolytic virotherapy

Indexed keywords

COLLAGEN TYPE 4; GELATIN; GELATINASE B; HERMES ANTIGEN; HYALURONIC ACID; ONCOLYTIC MYXOMA VIRUS; ONCOLYTIC VIRUS; PROTEIN KINASE B; RAPAMYCIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CELL INVASION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVATION; FEMALE; GALLBLADDER CANCER; GLIOMA CELL; HUMAN; HUMAN CELL; HYDRAULIC CONDUCTIVITY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MYXOMA VIRUS; NONHUMAN; ONCOLYTIC VIROTHERAPY; PROTEIN EXPRESSION; TUMOR XENOGRAFT; VIRUS REPLICATION; ZYMOGRAPHY; ANIMAL; DRUG EFFECTS; DRUG SCREENING; GALLBLADDER NEOPLASMS; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; TUMOR CELL LINE; VIROLOGY;

MUS; MYXOMA VIRUS;

ANIMALS; CELL LINE, TUMOR; GALLBLADDER NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYALURONIC ACID; IN VITRO TECHNIQUES; MICE; MYXOMA VIRUS; ONCOLYTIC VIROTHERAPY; SIROLIMUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84899475560     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-82     Document Type: Article

References (41)

1. Dutt UJ. Gall bladder cancer: can newer insights improve the outcome?. Gastroenterol Hepatol 2012, 27:642-653.
2. Piehler JM, Crichlow RW. Primary carcinoma of the gallbladder. Surg Gynecol Obstet 1978, 147:929-942.
3. Zeyaullah M, Patro M, Ahmad I, Ibraheem K, Sultan P, Nehal M, Ali A. Oncolytic viruses in the treatment of cancer: a review of current strategies. Pathol Oncol Res 2012, 18:771-781. 10.1007/s12253-012-9548-2, 22714538.
4. Wang F, Ma Y, Barrett JW, Gao X, Loh J, Barton E, Virgin HW, McFadden G. Disruption of Erk-dependent type I interferon induction breaks the myxoma virus species barrier. Nat Immunol 2004, 5:1266-1274. 10.1038/ni1132, 15502830.
5. Stanford MM, Werden SJ, McFadden G. Myxoma virus in the European rabbit: interactions between the virus and its susceptible host. Vet Res 2007, 38:299-318. 10.1051/vetres:2006054, 17296158.
6. Pal I, Mandal M. PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes. Acta Pharmacol Sin 2012, 33:1441-1458. 10.1038/aps.2012.72, 22983389.
7. Wang G, Barrett JW, Stanford M, Werden SJ, Johnston JB, Gao X, Sun M, Cheng JQ, McFadden G. Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proc Natl Acad Sci 2006, 103:4640-4645. 10.1073/pnas.0509341103, 1450224, 16537421.
8. Stanford MM, Shaban M, Barrett JW, Werden SJ, Gilbert PA, Bondy-Denomy J, Mackenzie L, Graham KC, Chambers AF, McFadden G. Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumor in vivo. Mol Ther 2008, 16:52-59. 10.1038/sj.mt.6300348, 17998900.
9. Lun XQ, Alain T, Zemp FJ, Zhou H, Rahman MM, Hamilton MG, McFadden G, Bell J, Senger DL, Forsyth PA. Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin. Cancer Res 2010, 70:598-608. 10.1158/0008-5472.CAN-09-1510, 20068158.
10. Lun XQ, Zhou H, Alain T, Sun B, Wang L, Barrett JW, Stanford MM, McFadden G, Bell J, Senger DL, Forsyth PA. Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhaneced by rapamycin. Cancer Res 2007, 67:8818-8827. 10.1158/0008-5472.CAN-07-1214, 17875723.
11. Misra S, Heldin P, Hascall VC, Karamanos NK, Skandalis SS, Markwald RR, Ghatak S. Hyaluronan-CD44 interactions as potential targets for cancer therapy. FEBS J 2011, 278:1429-1443. 10.1111/j.1742-4658.2011.08071.x, 3166356, 21362138.
12. Hodge-Dufour J, Noble PW, Horton MR, Bao C, Wysoka M, Burdick MD, Strieter RM, Trinchieri G, Pure E. Induction of IL-12 and chemokines by hyaluronan requires adhesion-dependent priming of resident but not elicited macrophages. J Immunol 1997, 159:2492-2500.
13. Noble PW, McKee CM, Cowman M, Shin HS. Hyaluronan fragments activate an NF-kappa B/I-kappa B alpha autoregulatory loop in murine macrophages. J Exp Med 1996, 183:2373-2378. 10.1084/jem.183.5.2373, 2192553, 8642348.
14. Yamalik N, Kilinc K, Caglayan F, Eratalay K, Caglayan G. Molecular size distribution analysis of human gingival proteoglycans and glycosaminoglycans in specific periodontal diseases. J Clin Periodontol 1998, 25:145-152. 10.1111/j.1600-051X.1998.tb02420.x, 9495613.
15. Auvinen P, Tammi R, Tammi M, Johansson R, Kosma VM. Expression of CD 44 s, CD 44 v 3 and CD44 v 6 in benign and malignant breast lesions: correlation and colocalization with hyaluronan. Histopathology 2005, 47:420-428. 10.1111/j.1365-2559.2005.02220.x, 16178897.
16. Kim MS, Park MJ, Moon EJ, Kim SJ, Lee CH, Yoo H, Shin SH, Song ES, Lee SH. Hyaluronic acid induces osteopontin via the phosphatidylinositol 3-kinase/AKT pathway to enhance the motility of human glioma cells. Cancer Res 2005, 65:686-691.
17. Mon NN, Hasegawa H, Thant AA, Huang P, Tanimura Y, Senga T, Hamaguchi M. A role for focal adhesion kinase signaling in tumor necrosis factor-alpha-dependent matrix metal-loproteinase-9 production in a cholangiocarcinoma cell line, CCKS1. Cancer Res 2006, 66:6778-6784. 10.1158/0008-5472.CAN-05-4159, 16818654.
18. Kuriyama N, Kuriyama H, Julin CM, Lamborn K, Israel MA. Pretreatment with protease is a useful experimental strategy for enhancing adenovirus-mediated cancer gene therapy. Hum Gene Ther 2000, 11:2219-2230. 10.1089/104303400750035744, 11084679.
19. Woo Y, Kelly KJ, Stanford MM, Galanis C, Chun YS, Fong Y, McFadden G. Myxoma virus is oncolytic for human pancreatic adenocarcinoma cells. Ann Surg Oncol 2008, 15:2329-2335. 10.1245/s10434-008-9924-z, 18454298.
20. Smallwood SE, Rahman MM, Smith DW, McFadden G. Myxoma virus: propagation, purification, quantification, and storage 2010, 1-24. Gainesville: Wiley-Liss, lnc, Curr Protoc Microbiol.
21. Huang CI, Kohno N, Ogawa E, Adachi M, Taki T, Miyake M. Correlation of reduction in MRP-1/CD9 and KAI1/CD82 expression with recurrences in breast cancer patients. Am J Pathol 1998, 153:973-983. 10.1016/S0002-9440(10)65639-8, 1853017, 9736046.
22. McGuire S, Zaharoff D, Yuan F. Nonlinear dependence of hydraulic conductivity on tissue deformation during intratumoral infusion. Ann Biomed Eng 2006, 34:1173-1181. 10.1007/s10439-006-9136-2, 16791492.
23. Kleiner DE, Stetler-Stevenson WG. Quantitative zymography: detection of picogram quantities of gelatinases. Anal Biochem 1994, 218:325-329. 10.1006/abio.1994.1186, 8074288.
24. Liu J, Wennier S, McFadden G. The immunoregulatory properties of oncolytic myxoma virus and their implications in therapeutics. Microbes Infect 2010, 12:1144-1152. 10.1016/j.micinf.2010.08.012, 2998584, 20832500.
25. Lun X, Yang W, Alain T, Shi ZQ, Muzik H, Barrett JW, McFadden G, Bell J, Hamilton MG, Senger DL, Forsyth PA. Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gilomas. Cancer Res 2005, 65:9982-9990. 10.1158/0008-5472.CAN-05-1201, 16267023.
26. Sauthoff H, Hu J, Maca C, Goldman M, Heitner S, Yee H, Pipiya T, Rom WN, Hay JG. Intratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: virus persists and spreads systemically at late time points. Hum Gene Ther 2003, 14:425-433. 10.1089/104303403321467199, 12691608.
27. Thorne SH, Hermiston T, Kirn D. Oncolytic virotherapy: approaches to tumor targeting and enhancing antitumor effects. Semin Oncol 2005, 32:537-548. 10.1053/j.seminoncol.2005.09.007, 16338419.
28. Peng KW, Hadac EM, Anderson BD, Myers R, Harvey M, Greiner SM, Soeffker D, Federspiel MJ, Russell SJ. Pharmacokinetics of oncolytic measles virotherapy: eventual equilibrium between virus and tumor in an ovarian cancer xenograft model. Cancer Gene Ther 2006, 13:732-738. 10.1038/sj.cgt.7700948, 16543921.
29. Guedan S, Rojas JJ, Gros A, Mercade E, Cascallo M, Alemany R. Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth. Mol Ther 2010, 18:1275-1283. 10.1038/mt.2010.79, 2911260, 20442708.
30. Brown E, McKee T, di Tomaso E, Pluen A, Seed B, Boucher Y, Jain RK. Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation. Nat Med 2003, 9:796-800. 10.1038/nm879, 12754503.
31. Cheng J, Sauthoff H, Huang Y, Kutler DI, Bajwa S, Rom WN, Hay JG. Human matrix metalloproteinase-8 gene delivery increases the oncolytic activity of a replicating adenovirus. Mol Ther 2007, 15:1982-1990. 10.1038/sj.mt.6300264, 17653103.
32. Park JB, Kwak HJ, Lee SH. Role of hyaluronan in glioma invasion. Cell Adh Migr 2008, 2:202-207. 10.4161/cam.2.3.6320, 2634087, 19262113.
33. Isacke C, Yarwood H. The hyaluronan receptor, CD44. Int J Biochem Cell Biol 2002, 34:718-721. 10.1016/S1357-2725(01)00166-2, 11950588.
34. Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 2000, 14:163-176. 316345, 10652271.
35. Yu Q, Stamenkovic I. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev 1999, 13:35-48. 10.1101/gad.13.1.35, 316376, 9887098.
36. Isnard N, Legeais JM, Renard G, Robert L. Effect of hyaluronan on MMP expression and activation. Cell Biol Int 2001, 25:735-739. 10.1006/cbir.2001.0759, 11482897.
37. Yokooo T, Kitammura M. Dual regulation of IL-1b-mediated matrix metalloproteinase-9 expression in mesangial cells by NFκB and AP-1. Am J Physiol 1996, 270:123-130.
38. Black KE, Colins SL, Hagan RS, Hamblin MJ, Chan-Li Y, Hallowell RW, Powell JD, Horton MR. Hyaluronan fragments induce IFNß via a novel TLR4-TRIF-IRF3-dpendent pathway. J Inflamm (Lond) 2013, 10:23. 10.1186/1476-9255-10-23, 3682892, 23721397.
39. Bourguigonon LY, Wong G, Earle C, Krueger K, Spevak CC. Hyaluronan-CD44 interaction promotes c-Src-mediated twist signaling, microRNA-10b expression, and RhoA/RhoC up-regulation, leading to Rho-kinase-associated cytoskeleton activation and breast tumor cell invasion. J Biol Chem 2010, 285:36721-36735. 10.1074/jbc.M110.162305, 2978601, 20843787.
40. Jin X, Jeon HY, Joo KM, Kim JK, Jin J, Kim SH, Kang BG, Beck S, Lee SJ, Kim JK, Park AK, Park WY, Choi YJ, Nam DH, Kim H. Frizzled 4 regulates stemness and invasiveness of migrating glioma cells established by serial intracranial transplantation. Cancer Res 2011, 71:3066-3075. 10.1158/0008-5472.CAN-10-1495, 21363911.
41. Kinugasa Y, Matsui T, Takakura N. CD44 expressed on cancer-associated fibroblasts is a functional molecule supporting the stemness and drug resistance of malignant cancer cells in the tumor microenvironment. Stem Cells 2014, 32:145-156. 10.1002/stem.1556, 24395741.